BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received
about
Cancer Hallmarks, Biomarkers and Breast Cancer Molecular SubtypesHow cell death shapes cancerPatient-derived xenograft models of breast cancer and their predictive powerProfiling of luteal transcriptome during prostaglandin F2-alpha treatment in buffalo cows: analysis of signaling pathways associated with luteolysisArtemin, a member of the glial cell line-derived neurotrophic factor family of ligands, is HER2-regulated and mediates acquired trastuzumab resistance by promoting cancer stem cell-like behavior in mammary carcinoma cells.Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER+ breast cancer.Age-associated prognostic and predictive biomarkers in patients with breast cancer.Comparison of methods for handling missing data on immunohistochemical markers in survival analysis of breast cancerSignificance of immunohistochemistry in breast cancerOverexpression of Bcl2 in osteoblasts inhibits osteoblast differentiation and induces osteocyte apoptosis.Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data.Differential expression of breast cancer-associated genes between stage- and age-matched tumor specimens from African- and Caucasian-American Women diagnosed with breast cancer.miR-21 Expression in Pregnancy-Associated Breast Cancer: A Possible Marker of Poor Prognosis.Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease.Prognostic value of mitotic index and Bcl2 expression in male breast cancer.Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review.Trefoil factor 3 promotes metastatic seeding and predicts poor survival outcome of patients with mammary carcinoma.New castanospermine glycoside analogues inhibit breast cancer cell proliferation and induce apoptosis without affecting normal cellsRegulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer.Breast cancer medications and vision: effects of treatments for early-stage disease.The role of Nanog expression in tamoxifen-resistant breast cancer cellsSensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737Immune microenvironment as a factor of breast cancer progression.Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy.S6K1 inhibition enhances the apoptotic cell death of breast cancer cells in response to Bcl-2/Bcl-xL inhibition by the downregulation of survivinComprehensive prognostic analysis in breast cancer integrating clinical, tumoral, micro-environmental and immunohistochemical criteriaExpression of alpha B crystallin and BCL2 in patients with infiltrating ductal carcinomaBCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis.Artemin stimulates radio- and chemo-resistance by promoting TWIST1-BCL-2-dependent cancer stem cell-like behavior in mammary carcinoma cells.An Epigenetic Pathway Regulates Sensitivity of Breast Cancer Cells to HER2 Inhibition via FOXO/c-Myc AxisA new genome-driven integrated classification of breast cancer and its implications.Astronomical algorithms for automated analysis of tissue protein expression in breast cancer.Biology of primary breast cancer in older women treated by surgery: with correlation with long-term clinical outcome and comparison with their younger counterpartsDoes the expression of BCL2 have prognostic significance in malignant peritoneal mesothelioma?Decline in Antigenicity of Tumor Markers by Storage Time Using Pathology Sections Cut From Tissue Microarrays.A BCL2 promoter polymorphism rs2279115 is not associated with BCL2 protein expression or patient survival in breast cancer patients.Ki67-BCL2 index in prognosis of malignant peritoneal mesothelioma.Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy.Immunophenotypic and genomic characterization of papillary carcinomas of the breast.Prognostic value of molecular markers and cytogenetic alterations that characterize breast cancer precursor lesions (Review)
P2860
Q26743510-EABB4B87-50F2-450D-AC0B-7DEA8FC712F5Q27021441-48C680A9-12C8-4C25-8D93-7AABC7C71B17Q27026531-A6231AF4-95D9-4017-9B86-344997B19C3CQ27316498-D31ECF2B-EFEC-4F80-80D5-1690C3E553A6Q33718457-83C7DE5C-A164-46F4-9946-541891BBB1B9Q33745649-A0621B8A-6325-45CB-8DDC-6EE4562A60B3Q33750880-75D1AB86-766B-4E43-BC43-8578C1F5D589Q33803680-4F633A24-44B7-46DB-B16E-67C3E82D7AE9Q34023682-861DEC43-3E29-4FC4-AD14-A6C7BC2BDEF7Q34082775-C486399C-6EFD-4ACF-AB64-F57F87E9ED75Q34198351-EA0817DF-A309-4463-B7EE-AA686E2ABEAEQ34278253-3A9EEB6A-6BA7-4D99-B050-26301138E9F8Q34575190-F54F326B-503D-4F72-8F0D-4AAE38CC75C5Q34577467-5D5EFE27-8BDD-4D07-BF25-E812CEB5A367Q34661870-A8A4C065-3762-4108-9C64-CB72C6BA4C8FQ34940834-7548F939-E7EA-419C-80E2-3334BCF3D62DQ35000231-9F23A145-A616-49F9-B036-5BB546440785Q35016962-8B30B4F9-6C51-409F-95CD-B168B8D00B5EQ35274741-30D8D6C6-204B-427F-AD05-8DFEEA742870Q35496778-5CB215D8-B6C6-4560-B399-BFF095B01994Q35703398-BC4C94D1-0737-4A96-9BAD-B1A87D14B7F0Q35779325-BF93AB08-4795-4B6F-A92E-D6B9EE974B8EQ35780464-0F917F8B-D0C1-4B31-86AB-304162ECA5BDQ35809680-D77DE543-204E-4247-BC73-489A9D9E4CC9Q35870533-73217CEF-D9BA-4586-A1F6-02EFC681186CQ36075768-C1F44089-25BD-4200-A432-87A08E150A7FQ36095069-55E1962B-54FA-4639-87EC-C5FC1749D7B0Q36284637-ABC728C5-EF5D-40C3-94E0-CC02D553D71FQ36466583-78294962-E8A2-4855-B5AC-08930E35DE26Q36566350-973120CE-61D7-4354-BAC5-732206BB63D9Q36664694-A4584B26-DE25-4D44-8FE3-5CA42307BDA1Q36671817-08E2D41A-1E1E-4922-84FD-A6A89750497AQ36746712-C2356CBF-080A-4575-91B6-CD9089A05F95Q36966828-906B0551-9603-4E66-8C5F-C74D9D682C51Q36967608-932D82E0-2985-4D72-84F9-71BA7EF906AEQ37052173-C331A1E8-755F-4C6D-8F23-CBB1C95613D1Q37096479-315C8C4C-1F9F-4A54-8DF0-0C18847C6868Q37097049-243BF1C2-FD09-412B-B551-320B319F6EF0Q37130628-A9A7C8EB-809F-4E6B-9656-1291DDC4568BQ37269644-B9E4E0B8-C406-4EAC-A26A-E20E3381250E
P2860
BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
BCL2 in breast cancer: a favou ...... t of adjuvant therapy received
@ast
BCL2 in breast cancer: a favou ...... t of adjuvant therapy received
@en
BCL2 in breast cancer: a favou ...... t of adjuvant therapy received
@nl
type
label
BCL2 in breast cancer: a favou ...... t of adjuvant therapy received
@ast
BCL2 in breast cancer: a favou ...... t of adjuvant therapy received
@en
BCL2 in breast cancer: a favou ...... t of adjuvant therapy received
@nl
prefLabel
BCL2 in breast cancer: a favou ...... t of adjuvant therapy received
@ast
BCL2 in breast cancer: a favou ...... t of adjuvant therapy received
@en
BCL2 in breast cancer: a favou ...... t of adjuvant therapy received
@nl
P2093
P2860
P50
P3181
P356
P1476
BCL2 in breast cancer: a favou ...... t of adjuvant therapy received
@en
P2093
C A McLean
D Huntsman
E Provenzano
G Turashvili
J Le Quesne
K E Driver
P2860
P2888
P304
P3181
P356
10.1038/SJ.BJC.6605736
P407
P577
2010-08-24T00:00:00Z
P5875
P6179
1037158386